PAOG Plans To Add CBD Nutraceutical Revenue In 2021 To Cannabis Cultivation Revenue
February 10 2021 - 9:32AM
InvestorsHub NewsWire
Sandusky, OH --
February 10, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc.
(USOTC:
PAOG) today announced the company plans to add revenue this
year in 2021 from its developing CBD nutraceutical business to
currently anticipated revenue from its cannabis cultivation
business revenue.
PAOG recently
announced that it anticipated reporting approximately $50,000 in
revenue in Q4 2020 from its cannabis cultivation business acquired
last year from Puration, Inc. (USOTC:
PURA). The Q4 2020 revenue anticipated to be reported
comes from a $300,000 sales agreement anticipated to generate
approximately $200,000 in revenue in the course of
2021.
PAOG has also
recently announced plans to introduce a variety of CBD
nutraceuticals. Today, the company adds that its CBD
nutraceutical products are anticipated to go into production this
year and begin contributing to
revenue.
PAOG plans to
publish a multimedia presentation next week on the company’s
strategy to expand its nutraceutical product
reach.
The company
recently announced plans to produce nutraceuticals for additional
applications beyond the current focus on care
for those
experiencing issues associated with Chronic Obstructive Pulmonary
Disorder (COPD).
The
presentation is scheduled to be published next week on Tuesday, Feb
16th.
Last year,
PAOG acquired
RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a
cannabis treatment under development for Chronic Obstructive
Pulmonary Disorder (COPD) derived from a patented cannabis
extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND
APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE
CANNABIS PLANT."
In addition to
PAOG’s ongoing efforts to develop a pharmaceutical treatment for
COPD, the company has announced engaging with
the Puerto Rico Consortium for Clinical Investigation (PRCCI) to
assist PAOG with developing its proprietary Cannabidiol (CBD)
extract into a nutraceutical product to provide care for those
experiencing issues associated with Chronic Obstructive Pulmonary
Disorder (COPD).
Last Thursday, PAOG revealed for the first
time a broader nutraceutical development initiative with plans to
produce nutraceuticals for additional applications. The CBD
nutraceutical market was valued at $3.8
billion in 2018 forecasted to grow at CAGR of over
18%.
PAOG plans to establish a revenue stream
this year from its nutraceuticals’ initiative adding to its
recently confirmed a $300,000 sales agreement executed by the
company’s cannabis cultivation subsidiary. PAOG anticipates
approximately $50,000 in revenue per quarter for six quarters
starting with an estimated $50,000 in revenue expected to be
reported for Q4 2020.
PAOG plans to
develop and distribute its CBD nutraceuticals with Alkame Holdings,
Inc. (OTC
Pink: ALKM) as a copacker and North American Cannabis Holdings,
Inc. (OTC
Pink: USMJ) as a
distributor.
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Sep 2023 to Sep 2024